Greenyn Biotechnology Co., Ltd.(TW:6846)
NT$49.00+-1.50 (+0.00%)
TW:6846
Greenyn Biotechnology Co., Ltd. financials statements
NT$49.00
At close:+-1.50 (+0.00%)
Greenyn Biotechnology Co., Ltd. (6846) Ratios
Greenyn Biotechnology Co., Ltd. Ratios
TW:6846's free cash flow for Q2 2026 was NT$-240.78M. For the 2026 fiscal year, TW:6846's free cash flow was decreased by NT$-254.66M and operating cash flow was NT$13.88M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Sep 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.84 | 4.14 | 2.75 | 2.95 | 3.62 |
| Quick Ratio | 6.02 | 3.45 | 2.19 | 2.23 | 3.01 |
| Cash Ratio | 3.65 | 2.71 | 1.74 | 1.64 | 1.89 |
| Solvency Ratio | 0.16 | 0.69 | 0.43 | 0.63 | 0.68 |
| Operating Cash Flow Ratio | 0.73 | 1.08 | 0.42 | 1.02 | 0.43 |
| Short-Term Operating Cash Flow Coverage | 145.92 | 0.00 | 0.98 | 7.66 | 4.09 |
| Net Current Asset Value | NT$ 353.79M | NT$ 584.66M | NT$ 476.50M | NT$ 393.24M | NT$ 450.78M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.43 | 0.06 | 0.17 | 0.10 | 0.08 |
| Debt-to-Equity Ratio | 0.94 | 0.08 | 0.25 | 0.15 | 0.11 |
| Debt-to-Capital Ratio | 0.48 | 0.07 | 0.20 | 0.13 | 0.10 |
| Long-Term Debt-to-Capital Ratio | 0.47 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.16 | 1.30 | 1.46 | 1.49 | 1.38 |
| Debt Service Coverage Ratio | 14.14 | 119.13 | 1.19 | 5.54 | 7.37 |
| Interest Coverage Ratio | 15.76 | 112.28 | 96.68 | 148.44 | 124.46 |
| Debt to Market Cap | 0.43 | 0.00 | 0.06 | 0.02 | 0.01 |
| Interest Debt Per Share | 34.36 | 2.50 | 7.63 | 3.56 | 2.94 |
| Net Debt to EBITDA | 0.55 | -2.26 | -1.75 | -1.35 | -1.48 |
| Profitability Margins | |||||
| Gross Profit Margin | 48.07% | 47.55% | 49.03% | 52.59% | 51.61% |
| EBIT Margin | 20.61% | 21.21% | 20.92% | 26.27% | 24.56% |
| EBITDA Margin | 24.48% | 24.71% | 24.03% | 29.83% | 27.92% |
| Operating Profit Margin | 20.61% | 19.22% | 19.96% | 26.27% | 24.56% |
| Pretax Profit Margin | 20.21% | 21.04% | 20.72% | 26.09% | 24.36% |
| Net Profit Margin | 15.90% | 16.72% | 16.32% | 20.80% | 19.14% |
| Continuous Operations Profit Margin | 15.90% | 16.72% | 16.32% | 20.80% | 19.14% |
| Net Income Per EBT | 78.67% | 79.48% | 78.79% | 79.74% | 78.56% |
| EBT Per EBIT | 98.05% | 109.44% | 103.76% | 99.33% | 99.20% |
| Return on Assets (ROA) | 6.90% | 13.17% | 11.25% | 17.58% | 15.72% |
| Return on Equity (ROE) | 14.87% | 17.15% | 16.40% | 26.11% | 21.63% |
| Return on Capital Employed (ROCE) | 9.97% | 18.55% | 18.68% | 30.41% | 25.95% |
| Return on Invested Capital (ROIC) | 7.78% | 14.53% | 12.65% | 22.78% | 19.57% |
| Return on Tangible Assets | 6.91% | 13.21% | 11.27% | 17.61% | 15.74% |
| Earnings Yield | 7.33% | 6.75% | 6.39% | 7.37% | 6.58% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.00 | 6.33 | 6.35 | 6.05 | 6.05 |
| Payables Turnover | 6.57 | 7.32 | 7.03 | 7.20 | 8.29 |
| Inventory Turnover | 2.68 | 3.26 | 2.39 | 2.05 | 2.90 |
| Fixed Asset Turnover | 1.59 | 3.82 | 3.70 | 5.37 | 5.07 |
| Asset Turnover | 0.43 | 0.79 | 0.69 | 0.84 | 0.82 |
| Working Capital Turnover Ratio | 0.96 | 1.49 | 1.64 | 1.51 | 1.56 |
| Cash Conversion Cycle | 132.91 | 119.72 | 158.20 | 187.65 | 141.93 |
| Days of Sales Outstanding | 52.15 | 57.68 | 57.47 | 60.33 | 60.28 |
| Days of Inventory Outstanding | 136.34 | 111.88 | 152.68 | 178.03 | 125.70 |
| Days of Payables Outstanding | 55.58 | 49.84 | 51.95 | 50.71 | 44.05 |
| Operating Cycle | 188.49 | 169.56 | 210.15 | 238.36 | 185.99 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 5.89 | 8.17 | 4.90 | 9.41 | 3.36 |
| Free Cash Flow Per Share | -8.75 | 7.81 | 1.46 | 8.71 | 2.63 |
| Dividend Paid and CapEx Coverage Ratio | 0.32 | 2.12 | 0.69 | 1.06 | 1.24 |
| Capital Expenditure Coverage Ratio | 0.40 | 22.47 | 1.42 | 13.40 | 4.61 |
| Operating Cash Flow Coverage Ratio | 0.17 | 3.34 | 0.65 | 2.68 | 1.17 |
| Operating Cash Flow to Sales Ratio | 0.17 | 0.25 | 0.16 | 0.33 | 0.12 |
| Free Cash Flow Yield | -11.90% | 9.70% | 1.84% | 10.67% | 3.17% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 13.64 | 14.77 | 15.65 | 13.58 | 15.20 |
| Price-to-Sales (P/S) Ratio | 2.17 | 2.48 | 2.56 | 2.82 | 2.91 |
| Price-to-Book (P/B) Ratio | 2.03 | 2.54 | 2.57 | 3.54 | 3.29 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -8.40 | 10.31 | 54.21 | 9.37 | 31.50 |
| Price-to-Operating Cash Flow Ratio | 12.49 | 9.85 | 16.09 | 8.67 | 24.67 |
| Price-to-Earnings Growth (PEG) Ratio | -12.39 | 1.82 | -0.97 | 1.35 | 7.39 |
| Enterprise Value Multiple | 9.40 | 7.77 | 8.88 | 8.12 | 8.94 |
| Enterprise Value | 2.11B | 1.68B | 1.71B | 1.71B | 1.73B |
| EV to EBITDA | 9.40 | 7.77 | 8.88 | 8.12 | 8.94 |
| EV to Sales | 2.30 | 1.92 | 2.13 | 2.42 | 2.50 |
| EV to Free Cash Flow | -8.92 | 7.99 | 45.27 | 8.03 | 27.04 |
| EV to Operating Cash Flow | 13.26 | 7.63 | 13.44 | 7.43 | 21.18 |
| Tangible Book Value Per Share | 36.14 | 31.56 | 30.67 | 22.96 | 25.19 |
| Shareholders’ Equity Per Share | 36.25 | 31.68 | 30.74 | 23.02 | 25.25 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.21 | 0.21 | 0.21 | 0.20 | 0.21 |
| Revenue Per Share | 33.90 | 32.49 | 30.88 | 28.89 | 28.54 |
| Net Income Per Share | 5.39 | 5.43 | 5.04 | 6.01 | 5.46 |
| Tax Burden | 0.79 | 0.79 | 0.79 | 0.80 | 0.79 |
| Interest Burden | 0.98 | 0.99 | 0.99 | 0.99 | 0.99 |
| Research & Development to Revenue | 0.05 | 0.06 | 0.07 | 0.08 | 0.08 |
| SG&A to Revenue | 0.20 | 0.22 | 0.22 | 0.20 | 0.20 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 |
| Income Quality | 0.86 | 1.20 | 0.77 | 1.25 | 0.48 |
Currency in TWD
